Pharma News

Associate Professor at the University of Oulu Teemu Myllylä, a leading expert in biomedical engineering, recently discussed his team’s groundbreaking work in brain health monitoring and early detection of neurodegenerative diseases at the recent 6G-enabled sustainable society event. Their research focuses on wearable technologies and direct sensing techniques for neurohydrodynamics, which have the potential to revolutionise the early diagnosis and treatment monitoring of Alzheimer’s disease.

IIHMR University, in partnership with the UNFPA Asia Pacific Regional Office, conducted a two-week International Training Program on Family Planning and Reproductive Health Commodity Security during September 18 to 29, 2023 at the university campus.

Fabre-Kramer Pharmaceuticals Inc. (Fabre-Kramer), a biopharmaceutical company committed to developing novel therapies to address unmet needs in psychiatry and neurology, is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved Exxua™ (gepirone hydrochloride extended-release tablets) for the treatment of major depressive disorder (MDD) in adults.

The World Health Organization (WHO) has recommended a new vaccine, R21/Matrix-M, for the prevention of malaria in children. The recommendation follows advice from the WHO: Strategic Advisory Group of Experts on Immunization (SAGE) and the Malaria Policy Advisory Group (MPAG) and was endorsed by the WHO Director-General following its regular biannual meeting held on 25-29 September.

Johnson & Johnson confirmed its intent not to enforce patents it owns and controls for SIRTURO® (bedaquiline) in the treatment of multidrug-resistant tuberculosis (MDR-TB) in 134 low- and middle-income countries.

AstraZeneca Pharma India Limited has received permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from Central Drugs Standard Control Organisation for Palivizumab (Synagis) solution for injection 100 mg/ml (r-DNA origin) (50mg/0.5mL & 100 mg/mL presentations in single-dose vials administered through intramuscular route).

Government to include Oseltamivir and Zanamivir in Schedule H1 after the consultation with the Drugs Technical Advisory Board.

The new policy, on environmental sustainability within pharmacy, expands on a 2016 FIP statement on the importance of reducing the environmental impact of pharmaceuticals and related activities. It makes clear that environmental sustainability includes both mitigation measures, such as reducing pharmaceutical pollution and greenhouse gas emissions, as well as adaptation measures to climate change.

How are environmental changes, loss of biodiversity, and the spread of pathogens connected? The answer is a puzzle. Researchers from Charité – Universitätsmedizin Berlin have now described one piece of that puzzle in the journal eLife,* showing that the destruction of tropical rainforests harms the diversity of mosquito species. At the same time, more resilient species of mosquitoes become more prevalent – which also means the viruses they carry are more abundant. If there are many individuals of a given species, those viruses can spread quickly.